Biogen Stock (BIIB): $325 Price Target From Jefferies

By Amit Chowdhry ● Jan 16, 2022
  • The shares of Biogen Inc (NASDAQ: BIIB) have received a price target of $325 from Jefferies. These are the details.

The shares of Biogen Inc (NASDAQ: BIIB) have received a price target of $325 from Jefferies. And Jefferies analyst Michael Yee is maintaining a “Buy” rating on the shares.

Yee pointed out that sentiment on Biogen remains strongly negative with Aduhelm almost, but not fully out of the stock price calculation. 

Plus Yee said $180-$200 per share is where Aduhelm would be basically out so there is still some downside. And on the good news side, there is a chance the final NCD will be less restrictive and the company is preparing to engage during the now-open 30-day review comments period to try to change the proposal before final issuance by April 11. 

Yee also explained that Biogen management said the company remains open to all options on the table and they mentioned they remain open to short-term and larger strategic measures to benefit shareholders. 

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.